Grimes Richard M, Grimes Deanna E
Department of Internal Medicine, Medical School, The University of Texas Health Science Center, Houston, Texas, USA.
J Int Assoc Physicians AIDS Care (Chic). 2009 Nov-Dec;8(6):364-6. doi: 10.1177/1545109709351240.
To determine 1) whether patients' statements of readiness to take HAART predicted adherence and 2) whether previous experience with HAART enabled patients to better predict adherence.
Thirty-nine patients (24 naïve to HAART and 15 reinitiating HAART after a hiatus of >6 months) indicated readiness to take HAART on a Likert scale and a visual analog scale (VAS). Adherence was measured by prescription renewals.
Participants were 72% male; 62% African/American; 23% Anglo-White, and 13% Hispanic. Patients considered themselves quite ready to initiate therapy on both scales. Adherence for 5 months ranged from 24% to 100%; mean = 68%; median = 78%. Adherence was not associated with readiness as measured by the Likert scale (F = .15, p = .86) or the VAS (r = -.078, p = .64). VAS readiness scores did not correlate with adherence for naïve (r = -.16; p = .47) or experienced (r = .09; p = .76) patients.
Patients' statements of readiness to take HAART do not predict their adherence.
1）确定患者对接受高效抗逆转录病毒治疗（HAART）的准备程度声明是否能预测其依从性；2）确定既往HAART治疗经历是否能使患者更好地预测依从性。
39名患者（24名初次接受HAART治疗，15名在中断超过6个月后重新开始HAART治疗）通过李克特量表和视觉模拟量表（VAS）表明接受HAART治疗的准备程度。通过处方续签来衡量依从性。
参与者中72%为男性；62%为非裔美国人；23%为英裔白人，13%为西班牙裔。患者在两种量表上都认为自己非常准备好开始治疗。5个月的依从性范围为24%至100%；平均为68%；中位数为78%。通过李克特量表（F = .15，p = .86）或VAS（r = -.078，p = .64）测量，依从性与准备程度无关。对于初次接受治疗（r = -.16；p = .47）或有治疗经验（r = .09；p = .76）的患者，VAS准备程度得分与依从性均无相关性。
患者对接受HAART治疗的准备程度声明不能预测其依从性。
